Concepedia

Andres Forero‐Torres

AF

Statistics

Publications

127

Citations

13.6K

H-Index

53

Active since

2004

Affiliations

University of Alabama at Birmingham(Current)

The University of Texas MD Anderson Cancer Center

Seagen (United States)

Memorial Sloan Kettering Cancer Center

Georgetown University

Andres Forero‐Torres is an author at University of Alabama at Birmingham specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2004–2024

127

Publications

127

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

, , +17

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text

, , +17

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 756 citations · Full text

, , +17

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

Rita Nanda, Minetta C. Liu, Christina Yau et al. · JAMA Oncology · 2020 · 706 citations · Full text

, , +16

1–5 of 127